Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research focused on Alemtuzumab and Multiple sclerosis, with related work in Interferon beta-1a, Relapsing remitting, Randomized controlled trial. Notable publications include 'Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial', 'Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial', and 'Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management'.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial